Features of correction associated with hyperprolactinemia menstrual dysfunction in adolescent girls
Keywords:adolescent girls, menstrual irregularities, Cyclodynon
Numerous studies have confirmed that the elevated prolactin level normalized when used in hyperprolactinemia drugs which contain the extract of Vitex agnus-castus. But in children’s gynecologist practice still there are cases when with restoring normal level of prolactin are persisted the delay of menstruation.
The aim of this study was the detection of causes of primary oligomenorrhea resistance to complex of non-hormonal therapy aimed at reducing prolactin level and normalization of menstrual function with the use of the drug Cyclodynon®.
For this aim surveyed 30 girls 13–17 years old with primary oligomenorrhea and hyperprolactinemia, non-associated with microadenomas pituitary. Patients received the restorative treatment (vitamin E, folic acid, glutamic acid, thiotriazoline), and at a deviation from the standard body mass indexes - the appropriate diet. All of girls received Cyclodynon® 1 tablet per day for three months. Depending on the state of menstrual function after 3 months of treatment the patients were divided into two groups: Group 1 with a satisfactory result (restored menstrual cycle) and group 2 – with unsatisfactory results (continuing delay menstruation).
It is shown that the using of Cyclodynon® drug in adolescents is effective for correction of hyperprolactinemia and to restore a regular menstrual cycle. It was found that all the patients on the background of three months acceptance this drug in combination with non-specific therapy, there was a normalization of prolactin level. Regular menstrual cycles with this medical complex was established in 70.0% of patients.
It was revealed that a prognostic criteria of efficacy of treatment include BMI value, circumference of waist, testosterone levels, distress syndrome at history and menstrual dysfunction in the mother. For synchronous change of body mass index, waist circumference and testosterone level for restore menstrual function needed the close cooperation with sick children gynecologist and pediatric endocrinologist, and drug correction of hyperprolactinemia not only, but also obesity and hyperandrogenism.
- Levenets, S.O., et al. “The prevalence of disorders of the reproductive system among modern girls and adolescent girls and risk factors of their origin.” Pediatrics, Obstetrics and Gynecology 6 (2010): 94–6.
- Morimatsu, Y., et al. “Future recovery of the normal menstrual cycle in adolescent patients with secondary amenorrhea.” J Obstet Gynaecol Res 3 (2009): 545–50.
- Tsikouras, P., et al. “Features of Polycystic Ovary Syndrome in adolescence.” J Med Life 8.3 (2015): 291–6.
- Tatarchuk, T.F., Ventskovskaia, I.B., Yefymenko, O.A. “Hyperprolactinemia in gynecologist practice.” International Journal of Endocrinology 1.7 (2007). Available from: [http://www.mif-ua.com/ archive/article/1944], last accessed Feb 20, 2017.
- Lee, D.Y., et al. “Prevalence of hyperprolactinemia in adolescents and young women with menstruation-related problems.” Am J Obstet Gynecol 206.3 (2012): 213–5.
- van Die, M.D., et al. “Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials.” Planta Med 79.7 (2013): 562–75.
- Gubler, E.V. Computational methods of analysis and recognition of pathological processes. Leningrad. Medicine (1978): 294 p.
- Levenets, S.A., Nachetova, T.A. “Hyperprolactinemia in adolescent girls with menstrual dysfunction and methods of its correction.” Women’s Health 4 (2010): 127–8.
- Kurlandskaia, R.M., Romantsova, T.I. “Effect of hyperprolactinemia on the basic parameters of lipid metabolism.” Attending physician 1 (2004). Available from: [http://www.lvrach.ru/2004/01/4530960/], last accessed Feb 20, 2017.
- Chaika, V.K., Vovk, I.B., Matytsina, L.A. Amenorrhea in adolescent girls. Kyiv. Health (2001): 655 p.
How to Cite
Copyright (c) 2017 С. И. Турчина, Т. А. Начетова, Н. А. Удовикова, О. Ю. Шелудько
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.